We use Google Analytics to see which pages are read and how the site is used, so we know what to improve. This only runs if you accept. See our privacy notice for details.

Dáil

Written answer

Vaccination Programme

Summary

A five-year shingles vaccination programme will begin in 2027, first covering immunocompromised people, then those aged 80 and over, and finally ages 65–69.

1767. Deputy Ryan O'Meara asked the Minister for Health the details of the shingles vaccination programme announced in budget 2027. [75768/26]

Comment on this

1850. Deputy Johnny Mythen asked the Minister for Health to provide an update on plans to make the shingles vaccine free for people aged over 65; and if she will make a statement on the matter. [76092/26]

Comment on this

2068. Deputy Ryan O'Meara asked the Minister for Health with regards to the new shingles vaccine programme recently announced, if the criteria have yet been established; the expected timeline for roll out; and if a person over 65, with chronic obstructive pulmonary disease, COPD, and a heart condition would qualify. [76798/26]

Comment on this

2193. Deputy John Lahart asked the Minister for Health when the shingles vaccination programme for adults aged 65 years and over will be implemented; and whether there are plans to extend eligibility to persons under 65 years, particularly those who are immunocompromised or otherwise at increased risk of shingles. [77334/26]

Comment on this

I propose to take Questions Nos. 1767, 1850, 2068 and 2193 together.

Ireland’s immunisation programme is informed by the advice of the National Immunisation Advisory Committee (NIAC). NIAC considers the prevalence of the relevant disease in Ireland as well as international best practice in relation to immunisation when developing its advice.

The current NIAC guidelines state that the shingles vaccine may be considered for those aged 65 years and older, due to the greater burden and severity of disease in this age group and in those aged 18 years and older at increased risk of shingles.

I can confirm that I have approved the introduction of a Shingles Vaccination Programme, in line with NIAC advice, to be implemented on a phased basis over 5 years, for immunocompromised groups and persons aged 65 and over.

The programme is expected to commence in 2027, initially offering shingles vaccines to immunocompromised groups. This will be followed by the 80 years and older cohort. The programme will conclude with the 65–69 year-old cohort.

It is expected that the vaccine will be administered in the main by GPs and Pharmacists. Further programme details will become available in due course.

Comment on this